Supplemental material for Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in the Treatment of Severe Dry Eye Disease: A Multicenter Randomized Trial by Andrea Leonardi, MD, Gysbert Van Setten, Mourad Amrane, Dahlia Ismail, Jean-Sebastien Garrigue, Francisco C. Figueiredo and Christophe Baudouin in European Journal of Ophthalmology</p
Dry eye syndrome (DES) is a multifactorial diseases with varying prevalence affecting great chunk of...
Purpose: Results from a 6-month double-masked and a 6-month open-label study (SANSIKA) established t...
La ciclosporina A es un inmunomodulador de uso tópico para el tratamiento del ojo seco; su uso tiene...
Purpose: The objective of this study was to report the evaluation of efficacy and safety of cyclospo...
Dry eye disease (DED) is a chronic inflammatory disease of the ocular surface requiring long-term th...
International audienceBackground: Cyclosporine A (CsA) has been used as a topical treatment for vari...
Background: Dry eye disease is a common ocular surface disease affecting tens of millions of people ...
Background: Dry eye disease is a common ocular surface disease affecting tens of millions of people ...
George D Kymionis, Dimitrios I Bouzoukis, Vassilios F Diakonis, Charalambos SiganosDepartment of Oph...
Dry eye syndrome (DES, Keratoconjunctivitis sicca) is a common disorder of the tear film caused by d...
To review the current treatment of chronic dry eye syndrome, focusing on cyclosporine A (CsA), a sys...
Purpose: To assess the safety and efficacy of cyclosporine A cationic emulsion (CsA CE) 0.1% eye dro...
Background/Objectives: Cyclosporine A cationic ophthalmic emulsion (CsA CE) was evaluated in paediat...
PURPOSE: Topical administration of the anti-inflammatory agent cyclosporin A (CsA) is recommended fo...
Purpose The purpose of this study was to report the efficacy of topical cyclosporine 0.05% at a fre...
Dry eye syndrome (DES) is a multifactorial diseases with varying prevalence affecting great chunk of...
Purpose: Results from a 6-month double-masked and a 6-month open-label study (SANSIKA) established t...
La ciclosporina A es un inmunomodulador de uso tópico para el tratamiento del ojo seco; su uso tiene...
Purpose: The objective of this study was to report the evaluation of efficacy and safety of cyclospo...
Dry eye disease (DED) is a chronic inflammatory disease of the ocular surface requiring long-term th...
International audienceBackground: Cyclosporine A (CsA) has been used as a topical treatment for vari...
Background: Dry eye disease is a common ocular surface disease affecting tens of millions of people ...
Background: Dry eye disease is a common ocular surface disease affecting tens of millions of people ...
George D Kymionis, Dimitrios I Bouzoukis, Vassilios F Diakonis, Charalambos SiganosDepartment of Oph...
Dry eye syndrome (DES, Keratoconjunctivitis sicca) is a common disorder of the tear film caused by d...
To review the current treatment of chronic dry eye syndrome, focusing on cyclosporine A (CsA), a sys...
Purpose: To assess the safety and efficacy of cyclosporine A cationic emulsion (CsA CE) 0.1% eye dro...
Background/Objectives: Cyclosporine A cationic ophthalmic emulsion (CsA CE) was evaluated in paediat...
PURPOSE: Topical administration of the anti-inflammatory agent cyclosporin A (CsA) is recommended fo...
Purpose The purpose of this study was to report the efficacy of topical cyclosporine 0.05% at a fre...
Dry eye syndrome (DES) is a multifactorial diseases with varying prevalence affecting great chunk of...
Purpose: Results from a 6-month double-masked and a 6-month open-label study (SANSIKA) established t...
La ciclosporina A es un inmunomodulador de uso tópico para el tratamiento del ojo seco; su uso tiene...